BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 34904510)

  • 1. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Pranzo G; Rodinò S; Scarcelli A; Zampaletta C; Brozzi L; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Fiorella S; Iannelli C; Larussa T; Le Grazie M; Luppino I; Meucci C; FaggianI R; Pagnini C; Perazzo P; Rodriguez-Castro KI; Sacco R; Sebkova L; Serio M; De Monti A; Picchio M; Napolitano D; Schiavoni E; Turchini L; Scaldaferri F; Pugliese D; Guidi L; Laterza L; Privitera G; Pizzoferrato M; Lopetuso LR; Armuzzi A; Elisei W; Maconi G; Papa A
    Expert Opin Biol Ther; 2022 Feb; 22(2):313-320. PubMed ID: 34904510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
    Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
    United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
    Macaluso FS; Fries W; Viola A; Centritto A; Cappello M; Giuffrida E; Privitera AC; Piccillo G; Magnano A; Vinci E; Vassallo R; Trovatello A; Belluardo N; Giangreco E; Camilleri S; Garufi S; Bertolami C; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Orlando A
    Inflamm Bowel Dis; 2021 Jan; 27(2):182-189. PubMed ID: 32083291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
    Mazza S; Piazza O Sed N; Conforti FS; Fascì A; Rimondi A; Marinoni B; Casini V; Ricci C; Munari F; Pirola L; Invernizzi P; Girelli C; Lupinacci G; Pastorelli L; Cavallaro F; Ferraris L; Colucci A; Amato A; Eugenio Tontini G; Vecchi M; Fiorino G; Caprioli F
    Clin Transl Sci; 2022 Jan; 15(1):172-181. PubMed ID: 34523800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease.
    Lovero R; Losurdo G; La Fortezza RF; Terracciano F; Biscaglia G; Martino G; Nardella M; Di Leo A; Principi M; Andriulli A; Bossa F
    Eur J Gastroenterol Hepatol; 2021 Feb; 32(2):201-207. PubMed ID: 33369956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Fiorino G; Ruiz-Argüello MB; Maguregui A; Nagore D; Correale C; Radice S; Gilardi D; Allocca M; Furfaro F; Martínez A; Danese S
    Inflamm Bowel Dis; 2018 Feb; 24(3):601-606. PubMed ID: 29462398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
    Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
    Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
    Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD).
    Bokemeyer B; Hlavaty T; Allez M; Selema P; Moosavi S; Cadatal MJ; Fowler H; Mueller M; Liau KF; Gisbert JP
    Expert Opin Biol Ther; 2023; 23(8):791-800. PubMed ID: 37038897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
    Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
    Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.
    Hanzel J; Jansen JM; Ter Steege RWF; Gecse KB; D'Haens GR
    Inflamm Bowel Dis; 2022 Mar; 28(4):495-501. PubMed ID: 34013959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease.
    Dipasquale V; Pellegrino S; Ventimiglia M; Cucinotta U; Citrano M; Graziano F; Cappello M; Busacca A; Orlando A; Accomando S; Romano C;
    Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1007-1014. PubMed ID: 35830365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.
    Kim NH; Lee JH; Hong SN; Yoon H; Kang HW; Lee SH; Im JP; Cha JM; Eun CS; Kim JW; Choi CH; Park DI
    J Gastroenterol Hepatol; 2019 Sep; 34(9):1523-1532. PubMed ID: 30828891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.
    Tursi A; Mocci G; Faggiani R; Allegretta L; Valle ND; Forti G; Franceschi M; Ferronato A; Gallina S; Larussa T; Luzza F; Lorenzetti R; Penna A; Rodino S; Sebkova L; Lauria A; Piergallini S; Pranzo G; Ricciardelli C; Zampaletta C; Elisei W; Picchio M
    Ann Gastroenterol; 2019; 32(4):392-399. PubMed ID: 31263362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study.
    Smits LJ; Derikx LA; de Jong DJ; Boshuizen RS; van Esch AA; Drenth JP; Hoentjen F
    J Crohns Colitis; 2016 Nov; 10(11):1287-1293. PubMed ID: 27095751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease.
    Ebada MA; Elmatboly AM; Ali AS; Ibrahim AM; Fayed N; Faisal AF; Alkanj S
    Int J Colorectal Dis; 2019 Oct; 34(10):1633-1652. PubMed ID: 31492986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study.
    Smith PJ; Critchley L; Storey D; Gregg B; Stenson J; Kneebone A; Rimmer T; Burke S; Hussain S; Yi Teoh W; Vazeille S; Serna S; Steel A; Derbyshire E; Collins P; Dibb M; Flanagan P; Probert C; Verma AM; Subramanian S
    J Crohns Colitis; 2022 Sep; 16(9):1436-1446. PubMed ID: 35390141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.